Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 20;40(18):2063-2064.
doi: 10.1200/JCO.21.02593. Epub 2022 Apr 4.

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia  1 , Christopher Melani  1 , Mark Roschewski  1 , Wyndham H Wilson  1
Affiliations
Comment

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to R. Lakhotia et al.
    Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Burke GAA, et al. J Clin Oncol. 2022 Jun 20;40(18):2064-2066. doi: 10.1200/JCO.21.02912. Epub 2022 Apr 4. J Clin Oncol. 2022. PMID: 35377710 No abstract available.

Comment on

References

    1. Burke GAA, Minard-Colin V, Auperin A, et al. Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: A multicenter phase II trial J Clin Oncol 393716–37242021 - PMC - PubMed
    1. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma N Engl J Med 3681408–14162013 - PMC - PubMed
    1. Meyer RM, Hryniuk WM, Goodyear MD.The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma J Clin Oncol 9339–3471991 - PubMed
    1. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH J Clin Oncol 183633–36422000 - PubMed
    1. Wenningmann N, Knapp M, Ande A, et al. Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring Mol Pharmacol 96219–2322019 - PubMed

MeSH terms

Supplementary concepts